Bristol Myers Squibb (BMY) shares edged 0.7% higher in intraday trading Friday after posting better-than-expected results and guidance as it be💫nefited from the addition of new drugs to its lineup.

The pharmaceutical company reported fourth quarter 澳洲幸运5官方开奖结果体彩网:earnings per share (EPS) of $1.70, with revenue rising 1% from a year ago to $11.48 billion. Both beat forecasts.

Bristol Myers Squibb said new product sales grew 66%, led by sales of its Reblozyl anemia medicine, which were 61% higher at $274 million, and its 𓂃Opdualag ꦇtreatment for advanced skin cancer, up 83% to $187 million.  

The company also posted solid sales for its two most popular drugs, blood t🦋hinner Eliquis and cancer immunotherapy Opdivo. Eliqu🉐is sales were up 7%, while Opdivo sales grew 8%.

CEO Christopher Boerner noted Bristol Myers Squibb “saw good performance” from its in-line and new products, adding that it took several actions in the quarter “to strengthen the company and build a foundation for ܫsustainable growth.”

Bristol Myers Squibb said it anti♎cipates 2024 EPS in the range of $7.10 to $7.40, exceeding estimates. It projects revenue growing by a low-single-digit percentage, with analysts looking for a rise of 1.9%.

Shares of Bristol Myers Squibb were 0.7% higher at $48.87 per share as of about 12:15 p.m. ET Friday following the news. However, they've been in a long downward slide, losing nearly 40% their value since hitting an all-time high in December 2022.